Research programme: HDL-related therapeutics - Esperion/University of Michigan

Drug Profile

Research programme: HDL-related therapeutics - Esperion/University of Michigan

Alternative Names: Paraoxonase research programme - Esperion Therapeutics/University of Michigan; Research programme: dyslipidaemia therapies - Pfizer/University of Michigan

Latest Information Update: 30 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Michigan
  • Developer Esperion Therapeutics; University of Michigan
  • Class Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Septic shock

Most Recent Events

  • 30 Apr 2007 NTTC project; made disc
  • 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
  • 01 Feb 2001 Preclinical development for Ischaemic heart disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top